HER2-positive breast cancers are more likely to have a pathologic complete response (pCR) to neoadjuvant chemotherapy, whereas reduced pCR rates are demonstrated in Luminal-type breast cancers (2, 3). Here, ERBB2 is linked to breast carcinoma.